Nubeqa
Nubeqa (darolutamide) — Bayer / Orion An androgen receptor inhibitor developed jointly by Bayer and Finnish company Orion, used in the treatment of non-metastatic castration-resistant prostate cancer. FDA approved in 2019.
E Detail aid
Patient brochure
Digital Patient profiles
Reprint carrier
Digital MVA
NUBEQA Brand book
